Biomarin Pharmaceuticals
(BMRN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 395,474 | 426,218 | 185,686 | 426,859 | 301,916 |
| Depreciation Amortization | 55,424 | 37,915 | 20,707 | 88,081 | 66,200 |
| Income taxes - deferred | 48,125 | 61,771 | 28,429 | 56,096 | 13,709 |
| Accounts receivable | -107,378 | -156,124 | -57,590 | -57,909 | -130,456 |
| Other Working Capital | -129,608 | -248,535 | -90,462 | -216,396 | -133,245 |
| Other Operating Activity | 466,313 | 238,420 | 87,624 | 276,110 | 269,090 |
| Operating Cash Flow | $728,350 | $359,665 | $174,394 | $572,841 | $387,214 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -18,715 | -6,695 | -11,470 | 222,768 | 126,065 |
| PPE Investments | -62,316 | -33,869 | -16,768 | -75,424 | -55,894 |
| Net Acquisitions | -285,193 | N/A | N/A | N/A | N/A |
| Purchase Sale Intangibles | -5,569 | -266 | 0 | -11,994 | -11,225 |
| Other Investing Activity | -5,569 | -266 | 0 | -10,853 | -10,084 |
| Investing Cash Flow | $-371,793 | $-40,830 | $-28,238 | $136,491 | $60,087 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | 0 | N/A | N/A | -494,987 | -494,987 |
| Common Stock Issued | 7,714 | 7,707 | 0 | 49,277 | 41,415 |
| Other Financing Activity | -53,265 | -51,089 | -38,779 | -80,737 | -75,734 |
| Financing Cash Flow | $-45,551 | $-43,382 | $-38,779 | $-526,447 | $-529,306 |
| Exchange Rate Effect | -3,740 | -4,479 | -1,416 | 4,830 | 2,326 |
| Beginning Cash Position | 942,842 | 942,842 | 942,842 | 755,127 | 755,127 |
| End Cash Position | 1,250,108 | 1,213,816 | 1,048,803 | 942,842 | 675,448 |
| Net Cash Flow | $307,266 | $270,974 | $105,961 | $187,715 | $-79,679 |
| Free Cash Flow | |||||
| Operating Cash Flow | 728,350 | 359,665 | 174,394 | 572,841 | 387,214 |
| Capital Expenditure | -62,316 | -33,869 | -16,768 | -85,424 | -65,894 |
| Free Cash Flow | 666,034 | 325,796 | 157,626 | 487,417 | 321,320 |